Malaysia
Search
Sign In
Change Password
Points
Sign Out
Gastroenterology
Top Medical News
Individuals with a family history of Barrett's oesophagus or oesophageal adenocarcinoma (OAC) are at risk of developing the said diseases, according to the results of a systematic review and meta-analysis.
Patients on uninterrupted periprocedural antithrombotic therapy have a negligible risk of significant bleeding associated with the placement of a percutaneous endoscopic gastrostomy (PEG) tube, a recent study has shown.
In the treatment of older patients with inflammatory bowel disease (IBD), vedolizumab is linked to a lower risk of infection-related hospitalization compared with antitumour necrosis factor-α (anti-TNF) agents, according to a study.
Clinical remission, endoscopic remission, and biomarker normalization show a positive association with adalimumab trough levels in patients with inflammatory bowel disease (IBD), reports a study. Moreover, adalimumab levels of ≥8.25 μg/mL correlate with deep remission.
The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.
Cannabis and cannabinoids are not effective in inducing clinical remission or reducing inflammation in patients with inflammatory bowel disease (IBD), but they appear to significantly improve patient-reported symptoms and quality of life (QOL), suggest the results of a systematic review and meta-analysis.
A 14-day quadruple therapeutic regimen containing vonoprazan – a first-in-class potassium-competitive acid blocker (P-CAB) with reportedly stronger acid inhibition than proton pump inhibitors – provided an excellent cure rate for Helicobacter pylori (H. pylori) infection in patients with high clarithromycin and quinolone resistance regardless of CYP3A4/5 genotypic polymorphism, according to the prospective VQ-HP trial presented at APDW 2021.
Special Reports
SALOFALK – Mesalazine 1.5 g PR granules
RB Health is committed to support healthcare quality improvement through CME activities that help physicians stay updated with the latest developments in medicine. At the RB symposium held in Kuala Lumpur, two distinguished speakers gave their insights into the management of acid reflux and sore throat – two of the most common reasons for patients to visit their doctors.
At the recent Takeda Malaysia Vocinti® (vonoprazan) launch, held in conjunction with the Annual Scientific Meeting of the Malaysian Society of Gastroenterology and Hepatology - GUT 2019 at Shangri-La Kuala Lumpur, Professor Akihito spoke about vonoprazan’s merits as an alternative to conventional proton pump inhibitors.
Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Recently, randomized controlled trials and guidelines have brought to light the benefits of extending the duration of H. pylori treatment. Below are summaries of guidelines and trials examining the regimens used to manage the infection.
Conference Reports
The potassium-competitive acid blocker vonoprazan appears to be more effective than proton pump inhibitors (PPIs) in healing severe erosive esophagitis and relieving the symptoms of gastroesophageal reflux disease (GERD), according to a meta-analysis presented at APDW 2021.
A 14-day quadruple therapeutic regimen containing vonoprazan – a first-in-class potassium-competitive acid blocker (P-CAB) with reportedly stronger acid inhibition than proton pump inhibitors – provided an excellent cure rate for Helicobacter pylori (H. pylori) infection in patients with high clarithromycin and quinolone resistance regardless of CYP3A4/5 genotypic polymorphism, according to the prospective VQ-HP trial presented at APDW 2021.
According to a Hong Kong study presented at APDW 2021, the use of proton pump inhibitors (PPIs) is not associated with adverse clinical outcomes in individuals with COVID-19.
The combination of reduced-dose S1 and oxaliplatin (SOx) chemotherapy preserves quality of life (QoL) and physical function in vulnerable older patients with metastatic colorectal cancer (mCRC), according to a subgroup analysis of the NORDIC9* study presented at ESMO GI 2021.
Antibiotic exposure may be associated with an increased risk of early-onset colorectal cancer (CRC), according to a study from Scotland presented at ESMO GI 2021.
The treatment of gastroesophageal reflux disease (GERD) continues to rely on proton pump inhibitors (PPIs), but advances in the field take account of new management options, such as antireflux surgery for reflux hypersensitivity and diaphragmatic breathing in refractory GERD or rumination, as pointed out during a lecture presented at this year’s virtual Asian Pacific Digestive Week (APDW 2021).
During the coronavirus disease 2019 (COVID-19) pandemic, burnout has become prevalent among gastroenterologists in Southeast Asia, driven strongly by fears of getting infected and the stress of reduced income, according to a Singapore study presented at the recently concluded Asian Pacific Digestive Week 2021 (APDW 2021).